Adaptimmune Therapeutics ADAP reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Earnings
Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus an estimate of $-0.25.
Revenue was up $2.44 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.17 which was followed by a 1.3% increase in the share price the next day.
Here's a look at Adaptimmune Therapeutics's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.22 | 0.14 | -0.26 | -0.24 |
| EPS Actual | -0.05 | -0.04 | -0.30 | -0.24 |
| Revenue Estimate | 3.29M | 96.45M | 1.37M | 1.36M |
| Revenue Actual | 3.58M | 1.42M | 1.20M | 3.10M |
To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.